Metropolis Healthcare has launched a Centre for Genomics to expand its specialty diagnostics business. The company plans to ...

VEXAS syndrome is a rare adult-onset inflammatory disease linked to bone-marrow mutations. Doctors explain why it is often ...

Search ends for mountain lion in fatal New Year's Day Colorado attack Charlie Hunnam's girlfriend asked him to stop doing Ed Gein voice at home Michael Burry's big play off the US.-Venezuela situation ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Companies are looking for ways to use AI to power activities like coding in different languages and drafting legal contracts. Enterprises spend millions to build and train their own proprietary ...

A deep learning algorithm called FaceAge could allow clinicians to improve their qualitative assessments, and possibly catch ...

Nuclear weapons tests were once a regular occurrence, but most countries haven’t tested in decades, following the adoption of the Comprehensive Nuclear-Test-Ban Treaty in 1996. Now, that moratorium ...

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best AI stocks to buy according to analysts. On December 8, TD Cowen reaffirmed its Hold rating on Tempus AI, Inc. (NASDAQ:TEM), with an $88 price target.

US FDA Approves Fortress Bio and Zydus' Treatment for a Rare Pediatric Disease The U.S. Food and Drug Administration approved Fortress Biotech and Indian drugmaker Zydus Lifesciences' drug for ...

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...